EpiVax Therapeutics, Inc. (EVT) is a next generation precision immunotherapy company with an innovative technology for designing highly specific, personalized tumor-targeting immune therapies that can effectively train the patient’s immune system to fight cancer. These customized therapies can be delivered to patients at record speed, promoting optimal outcomes. Animal studies show that EVT therapies are effective and highly immunogenic. EVT has completed preclinical work and is ready to file IND and start a clinical trial. EVT’s technology is trade secret and IP protected.